THE FUTURE OF GYNAECOLOGICAL
HEALTH IS HERE
Revolutionary Microbiome-aligned Solutions by Avodes
Bacterial Vaginosis
BV and VVC (Candidiasis) are the most common vaginal infections in women of childbearing age, including pregnant women. 1
75%
of women will have at least one episode of
Vulvovaginal Candidiasis (VVC). 5
Antibiotics
are used to treat BV. At the same time, they cause Candidiasis:
Broad-spectrum antibiotics, which kill a range of bacteria, also kill healthy bacteria in your vagina, leading to overgrowth of Candida. 6
68%
of the G. vaginalis strains (one of the main bacteria causing BV) are already resistant to metronidazole. 7
OUR SOLUTIONS
A shift from symptom suppression to
root-cause correction: regain your healthy microbiome !
MICROBIOME-ALIGNED
SOLUTION
Our unique biotechnological peptides based treatment for Bacterial Vaginosis and Candidiasis selectively inhibits pathogens and protects Lactobacilli.
​
Avodes dual mechanism (antimicrobial peptides + microbiome-supportive system) is distinct from conventional treatments that are single-action:
​
-
Antibiotics/Antifungals: Kill pathogens but disrupt the vaginal microbiome, cause antimicrobial resistance and recurrence of infections.
-
Probiotics Alone: Focus on reintroducing beneficial bacteria but vaguely target pathogens directly.
OUR COMMITMENT
Revolutionizing the Solutions for Gynaecological Conditions with Targeted solution
At Avodes, we are committed to revolutionizing the solutions for gynaecological conditions. We believe in using microbiome-aligned solution to provide safe, effective, and innovative treatment that improve the lives of women.
Avodes PIPELINE
Indication
Research
Microbiological testings
Pre-Clinical
Clinical
Avodes Gel
BV and VVC treatment
Avodes Sponge
BV and VVC treatment/ prevention
Spomfy
Menstrual sponge
EU Project
I
"AvodÄ—s", JSC together with its partner "VaizduotÄ—", JSC is implementing the project "R&D for the development of innovative biotechnology based treatment of Bacterial Vaginosis and Candidasis" No. 02-019-K-0018. During the project, R&D activities will address identified scientific uncertainties and develop an innovative product - Avodes gel for the treatment of Bacterial Vaginosis and Candidasis.
The project is being implemented according to the 2022-2030 Development Program managed by the Ministry of Economy and Innovation of the Republic of Lithuania, under the Economic Transformation and Competitiveness Development Program, progress measure No. 05-001-01-05-07 "Create a coherent system for promoting innovation," activity "Promote the supply of innovations," sub-activity "Invest in activities for the development of new high value-added products and create conditions for researchers to participate in company R&D activities, promote intellectual property, early-stage pilot production of newly created products, preparation for the market."
The total value of the project is EUR 1 552 734, with funding of EUR 1 190 492, financed by the European Regional Development Fund.
The project implementation period is from 2024-07-15 to 2026-07-15.
We’re changing the future of vaginal microbiome health worldwide.
OUR PARTNERS
Avodes works with a range of partners in the healthcare industry to provide the best biotechnological solutions for the treatment of gynaecological conditions.
